Tweet
Influenza Other Respir Viruses. 2017 Nov 10. doi: 10.1111/irv.12520. [Epub ahead of print]
2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.
Kissling E1, Valenciano M1, Pozo F2, Vilcu AM3, Reuss A4, Rizzo C5, Larrauri A6,7, Horv?th JK8, Brytting M9, Domegan L10, Korczyńska M11, Meijer A12, Machado A13, Ivanciuc A14, Vi?ekruna Vučina V15, van der Werf S16, Schweiger B17, Bella A5, Gherasim A6, Ferenczi A8, Zakikhany K9, O Donnell J10, Paradowska-Stankiewicz I11, Dijkstra F12, Guiomar R13, Lazar M14, Kurečić Filipović S15, Johansen K18, Moren A1; I-MOVE/I-MOVE+ study team19.
Author information
Abstract
BACKGROUND:
During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.
METHODS:
We used the test negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.
RESULTS:
We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0-14, 15-64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively.
CONCLUSIONS:
VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Case control study; Influenza; influenza vaccine; multicentre study; vaccine effectiveness
PMID: 29125681 DOI: 10.1111/irv.12520
Free full text
2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.
Kissling E1, Valenciano M1, Pozo F2, Vilcu AM3, Reuss A4, Rizzo C5, Larrauri A6,7, Horv?th JK8, Brytting M9, Domegan L10, Korczyńska M11, Meijer A12, Machado A13, Ivanciuc A14, Vi?ekruna Vučina V15, van der Werf S16, Schweiger B17, Bella A5, Gherasim A6, Ferenczi A8, Zakikhany K9, O Donnell J10, Paradowska-Stankiewicz I11, Dijkstra F12, Guiomar R13, Lazar M14, Kurečić Filipović S15, Johansen K18, Moren A1; I-MOVE/I-MOVE+ study team19.
Author information
Abstract
BACKGROUND:
During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.
METHODS:
We used the test negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.
RESULTS:
We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0-14, 15-64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively.
CONCLUSIONS:
VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Case control study; Influenza; influenza vaccine; multicentre study; vaccine effectiveness
PMID: 29125681 DOI: 10.1111/irv.12520
Free full text